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Multiple myeloma (MM) progression and myeloma-associated bone disease (MBD) are
highly dependent on bone marrow mesenchymal stromal cells (MSCs). MM-MSCs exhibit
abnormal transcriptomes, suggesting the involvement of epigenetic mechanisms governing
their tumor-promoting functions and prolonged osteoblast suppression. Here, we identify
widespread DNA methylation alterations of bone marrow-isolated MSCs from distinct MM
stages, particularly in Homeobox genes involved in osteogenic differentiation that associate
with their aberrant expression. Moreover, these DNA methylation changes are recapitulated
in vitro by exposing MSCs from healthy individuals to MM cells. Pharmacological targeting of
DNMTs and G9a with dual inhibitor CM-272 reverts the expression of hypermethylated
osteogenic regulators and promotes osteoblast differentiation of myeloma MSCs. Most
importantly, CM-272 treatment prevents tumor-associated bone loss and reduces tumor
burden in a murine myeloma model. Our results demonstrate that epigenetic aberrancies
mediate the impairment of bone formation in MM, and its targeting by CM-272 is able to
reverse MBD.
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Multiple myeloma (MM) is an incurable hematologicalmalignancy characterized by clonal expansion ofplasma cells in the bone marrow (BM) that accounts
for 1% of all cancers1,2. Nearly 90% of myeloma patients suffer
from skeletal-related events during the course of the disease,
including severe bone pain, hypercalcemia, pathological frac-
tures, and spinal cord compression3, that not only affect the
quality of life but also their overall survival4. Myeloma-
associated bone disease (MBD) is characterized by an increase
in bone-resorptive activity and number of osteoclasts (OCs), as
well as impairment of bone-forming activity and differentiation
of osteoblasts (OBs), which ultimately lead to the development
of osteolytic lesions5.
In most cases, symptomatic myeloma is preceded by
sequential asymptomatic stages of monoclonal gammopathy of
undetermined significance (MGUS) and smoldering myeloma
(SMM), with increasing BM plasmocytosis and monoclonal
component as well as augmented risk of progression to active
MM6,7. The biological behavior and clinical outcome of MM
are partly dependent on genetic and epigenetic abnormalities of
tumor subclones that arise from MGUS and SMM stages8.
However, the clinical stability of MGUS cases, despite dis-
playing shared genetic lesions with MM cells, suggests that the
BM microenvironment may critically modulate disease
progression6,9,10. In this regard, it has been widely shown that a
complex and bidirectional relationship exists between MM cells
and the BM niche, which results in oncogenesis support, ane-
mia, immunosuppression, and uncoupling of the bone remo-
deling process11.
Mesenchymal stromal cells (MSCs) are an essential cell type
in the formation and function of the BM microenvironment,
being the progenitors of bone-forming OBs, adipocytes, and
chondroblasts, as well as the hematopoietic-supporting stroma
components of the BM12. It is well-documented that BM-
derived MSCs from MM patients contribute to MM progression
(reviewed in ref. 11) and show an impaired ability to differ-
entiate into OBs13,14. Moreover, MM-MSCs are considered
inherently abnormal, as their dysfunctionality remains even
following ex vivo culture in the absence of MM cells15. Fur-
thermore, bone lesions persist in many MM patients even after
therapeutic remission, suggesting a long-term defect in MSCs
that inhibit their ability to properly differentiate into functional
OBs16.
Previous studies described that MSCs from MM patients are
cytogenetically normal17,18, but show alterations in their
transcriptional13,19 and proteomic11 profiles even in the absence
of myeloma cell interaction. This suggests that epigenetic
mechanisms could be governing the tumor-promoting functions
of MSCs and their prolonged OB suppression in MM. In fact,
Adamik and colleagues20 reported abnormal recruitment of
chromatin remodelers in MSCs from myeloma patients, con-
tributing to the transcriptional repression of Runx2, a master
regulator of OB differentiation. Yet, there is a lack of information
about DNA methylation-related mechanisms that may contribute
to MM progression and subsequent bone defects. DNA methy-
lation is an essential epigenetic modification involving the addi-
tion of a methyl group to the 5-carbon of the cytosine ring by a
family of DNA methyltransferase (DNMT) enzymes21, which has
been described to play a critical role in MSC lineage determina-
tion22, as well as in tumor progression and immunosuppression
in other cancer types23.
In this study, we identify DNA methylation alterations in
MSCs of MM patients mediated by MM cells resulting in the
dysregulation of osteogenesis, and this is reversed by the treat-
ment with CM-272, a dual inhibitor of DNMTs and the histone
methyltransferase G9a.
Results
BM-derived MSCs of distinct MM stages exhibit altered DNA
methylation profiles. We first obtained genome-wide DNA
methylation profiles of BM-derived MSCs isolated at different
stages of MM (newly diagnosed MGUS, high-risk SMM, and
MM) and healthy controls. DNA methylation changes were
identified using two different statistical approaches (Fig. 1A): (i)
detection of differentially methylated CpG positions (DMPs)
based on differences in DNA methylation means between the
patient (MGUS, SMM, and MM) and healthy MSCs (Δβ ≥ 0.1
and **p < 0.01) (Supplementary Data 1); and (ii) detection of
differentially variable CpG positions (DVPs) based on differences
in variance of DNA methylation levels (qval < 0.05 and *p < 0.05)
between the sample groups (Supplementary Data 2). In regards to
DMPs, the largest number of altered CpGs was found in MSCs
from patients of the SMM stage compared to healthy donors
(Supplementary Fig. 1A, B). On the other hand, we observed the
highest number of DVPs in comparison to healthy donors in
MSCs isolated from MGUS followed by SMM and MM patients
(Supplementary Fig. 1C, D), supporting the notion that these
stochastic and heterogeneous DNA methylation patterns are
associated with early stages of carcinogenesis, as previously
reported24,25. We also observed that the majority of identified
DMPs and DVPs are disease stage-specific, although the
asymptomatic stages showed a moderate proportion of overlap
(Fig. 1A).
Given that myeloma is a multi-stage disease, we then analyzed
the accumulative changes of DNA methylation associated
with MM progression by selecting DMPs (Supplementary Data 3)
and DVPs (Supplementary Data 4) that were found either only in
the MM stage, shared by SMM and MM and in all three
stages (Fig. 1A). With this analysis, we identified 872 hyper-
and 951 hypomethylated DMPs, and 260 hyper- and 318
hypomethylated DVPs.
Analyzing the distribution of MM progression-associated
CpGs in relation to CpG islands (CGI), we observed a significant
enrichment of CpGs in open sea regions in the hypomethylated
DMP data set (Fig. 1B) and in CpG islands in the hypermethy-
lated DVP data set (Supplementary Fig. 1E). Utilizing publicly
available chromatin state maps of BM-derived MSCs from
healthy individuals26, we found a significant enrichment of both
hyper- and hypomethylated DMPs sites that correspond to
enhancers (Fig. 1C). In addition, we observed an enrichment in
flanking transcription start sites (TSS) in the hypomethylated set,
and regions repressed by Polycomb Group (PcG) in hypermethy-
lated CpGs (Fig. 1C). On the other hand, hypermethylated DVPs
were enriched in TSSs, bivalent regions, and regions repressed by
Polycomb (Supplementary Fig. 1F).
To determine whether these MM progression-associated loci
shared any common DNA elements, we performed a search for
enriched transcription factor (TF)-binding sites in these regions
using the HOMER algorithm27. We observed a significant over-
representation of binding sites for the Runt and Tead family in
differentially hypermethylated DMPs associated with MM
progression (**p < 0.01; Fig. 1D). These results suggest that
key transcription factors involved in the upregulation of
osteogenic genes, such as RUNX228 or TEAD229, may
participate in aberrant DNA hypermethylation. Since DNA
methylation has been originally linked to transcriptional
repression, these results suggested that the hypermethylation
of these regions could compromise the ability of MSCs to
undergo proper OB differentiation. On the other hand, DMP
sites that experienced aberrant DNA hypomethylation were
highly enriched in binding motifs of the bZip and Homeobox
families (**p < 0.01; Fig. 1D). In this respect, the loss of DNA
methylation could be selectively driving the occupancy of TF
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that have been reported as negative regulators of OB
differentiation such as HOXA230 and ATF331. In addition, we
observed transcriptional deregulation of some members of
these TF families using expression array data from BM-derived
MSCs of healthy controls, MGUS, SMM, and MM patients.
Some of these TFs were specifically downregulated in MSCs of
active myeloma (RUNX2 and TEAD2), others were already
downregulated in precursor myeloma stages (HOXC9 and
CEBPD), whereas other TFs, including HOXA2 and ATF3, did
not change their expression in any myeloma stages
(Supplementary Fig. 1G). In all, these findings suggested that
MM progression-associated DNA methylation changes in
MSCs might be mediated by the sequential activity of specific
TF families, which are also functionally deregulated in MM32.
Furthermore, other genes that play important roles in the
pathophysiology of MM (such as the cytokines IL6 and OSM)
and associated MBD (secreted factors such as RANKL, SFRP2,
IL7, CHSY1, COL4A1, and the transcriptional repressor GFI1)
were also found to alter their DNA methylation levels (Fig. 1E
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Aberrant DNA methylation is associated with differential
Homeobox gene expression in MSCs at different MM stages.
To further investigate the relationship between differential DNA
methylation and gene expression, we mapped the DMPs to the
most proximal gene. Using expression array data from BM-
derived MSCs of healthy controls, MGUS, SMM, and MM
patients (Supplementary Data 5), differential expression of DMP-
associated genes was identified using a cutoff of *p < 0.05 com-
paring MGUS/SMM/MM to healthy controls for both DNA
methylation and gene expression (Fig. 2A and Supplementary
Data 6). Gene ontology (GO) analysis revealed that the genes
displaying both differential methylation and expression were
enriched in functional categories important in cell fate commit-
ment and bone phenotype (Fig. 2B). The most enriched func-
tional category corresponded to genes from the Homeobox
family. Within the Homeobox family, we found the subset of Hox
genes that encodes a large family of highly conserved TFs
responsible for driving the correct differentiation of MSCs33,
namely genes belonging to the HOXA-to-D clusters. Further-
more, we observed a significant enrichment in genes reported to
be downregulated in MM-MSCs (Fig. 2B)13. Integration of
methylation and gene expression data corresponding to the
Homeobox and bone formation-related genes revealed that both
DNA hyper- and hypomethylation events were associated with
both downregulation and upregulation of gene expression in
different genomic locations (Fig. 2C). Specifically, hypermethy-
lated genes that showed a reduced expression in patient MSCs
include positive regulators of OB differentiation such as RUNX2
or NRP234 (Fig. 2C and Supplementary Table 1) In contrast,
negative regulators of osteogenesis such as SFRP235 or NFATC236
were hypomethylated and consequently upregulated in patient
MSCs (Fig. 2C). In all, these factors could potentially contribute
to impaired osteoblastogenesis associated with bone disease in
MM and this is summarized in Supplementary Table 1.
Upon a closer inspection of several Homeobox-associated
genomic regions, we observed a negative correlation between
DNA methylation of promoters and gene expression. Specifically,
the HOXA gene cluster showed aberrant hypomethylation at the
HOXA4 promoter, and its gene expression was upregulated at
different disease stages. Conversely, gene promoters of HOX-A6,
-A7, -A9, -A10, and -A11 displayed hypermethylation and these
genes were downregulated in MGUS/SMM/MM (Fig. 2D and
Supplementary Fig. 2A). A similar pattern of an inverse
association between methylation and expression was observed
in the HOXB and HOXC gene cluster, where HOXB5, -C5, and
-C8 were aberrantly hypomethylated and upregulated, whereas
HOXC9, -C10, and -C11 were hypermethylated and down-
regulated in patients (Fig. 2D and Supplementary Fig. 2A). Other
Homeobox genes such as TBX5, PITX1, or EMX2 were also
reported as regulators of bone formation37–39 and showed an
association between DNA methylation at gene promoter and gene
expression (Fig. 2D and Supplementary Fig. 2A, B).
We then validated the aforementioned DNA methylation and
gene expression changes in an independent cohort of BM-derived
MSCs from different MM disease stages by pyrosequencing and
real-time quantitative PCR. Among the differentially methylated
genes of the Homeobox family, we selected HOXA2, -A4, -A6,
-A9, -A10, -B7, -C9, -C10, and PITX1 on the basis of their
reported role in MSC pluripotency (Fig. 2E, F and Supplementary
Fig. 2C, D)40. Furthermore, we validated differentially methylated
genes with osteogenic roles in the myeloma context, including
RUNX2 and IBSP (Fig. 2E, F and Supplementary Fig. 2C, D). In
most cases, we observed that DNA methylation negatively
correlated with gene expression.
Healthy MSCs change their DNA methylation profile to one
partially resembling that of MSCs from MM patients upon
interaction with MM plasma cells. To address the potential
contribution of MM cells in mediating aberrant DNA methyla-
tion changes in MSCs, we evaluated whether the epigenetic
changes observed in MM-MSCs could be mimicked in vitro by
direct contact of healthy MSCs with MM cells. Thus, we co-
cultured BM-derived MSCs from healthy donors with the human
MM cell line MM.1S for 2 weeks Subsequently, MSCs were sorted
by CD13+ expression and subjected to DNA methylation analysis
(Fig. 3A).
Under these conditions, MM.1S cells were able to induce the
expression of genes known to be upregulated in MM-MSCs
(IL1B, IL6, and HGF) in HD-MSCs compared with mono-
cultured HD-MSCs (Fig. 3B). Additionally, we validated the
inhibitory effect of MM cells in MSC-to-OB differentiation and
observed a decrease in both ALP activity and OB mineralization
in OBs differentiated in the presence of conditioned media from
the MM.1S cell line as compared to OBs differentiated alone
(Fig. 3C).
We then investigated the DNA methylation profiling of MSCs
from healthy donors generated upon interaction with MM cells.
We observed that 142 CpGs that change their methylation levels
upon co-culture with MM.1S cells were shared with aberrant
DNA profiles found in MSCs isolated from MGUS/SMM/MM
patients (Fig. 3D and Supplementary Data 7). Although this
accounted for a small percentage of DMPs identified in MM
patient MSCs, GO analyses revealed enrichment in Homeobox
genes and categories related to bone formation, similar to that
observed in primary patient MSCs (Fig. 3E). Specifically, we
found that healthy MSCs exposed to MM cells underwent gains
(HOXA9, ACVR2A, EBF2) and losses (HOXA2, HOXA3,
HOXC5) of DNA methylation in the direction of those observed
for MSCs from myeloma patients (Fig. 3F).
Fig. 1 High-throughput stepwise DNA methylation changes in BM-derived MSCs associated with MM progression. A Workflow depicting the
methodological approach for selecting DNA methylation changes in bone marrow-derived mesenchymal stromal cells (BM-MSCs) from monoclonal
gammopathy of undetermined significance (MGUS; n= 10), smoldering myeloma (SMM; n= 8), and multiple myeloma (MM; n= 9) patients versus
healthy controls (HD; n= 8). An example of a CpG site experiencing increased mean (differentially methylated position, DMP) or variance (differentially
variable position, DVP) in the disease versus the control condition is shown. Venn diagrams show the number of DMPs or DVPs resulting from each
comparison. B Distribution of DNA methylation changes in relation to CpG islands (CGI), including shores (south, S; north, N), shelves (south, S; north, N),
and open sea regions for differentially hyper- or hypomethylated CpG sites. C Enrichment analysis of differentially hyper- and hypomethylated CpG sites
located in different genomic regions, annotated by 15 chromHMM states. Color scale refers to log odd ratio and circle size refers to p-value significance.
D Bubble plot representation of HOMER transcription factor (TF) motif enrichment analysis of differentially hyper- and hypomethylated CpGs in MSCs
during MM progression (left and right panel, respectively). Color range depicts different transcription factor families and circle size refers to p-value
significance. E Box plots showing β-values from DMPs obtained from the EPIC array in MSCs from healthy donors and MGUS, SMM, and MM patients of
relevant genes involved in the pathogenesis of MM and associated bone disease. HD is represented in dark blue, MGUS in light blue, SMM in orange, and
MM in red. eBayes-moderated ANOVA t-test was performed to calculate statistical significance (*p < 0.05, **p < 0.01, and ***p < 0.005).
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Moreover, we validated the DNA methylation and gene
expression changes in healthy MSCs driven by co-culture with
MM.1S with another MM cell line, RPMI-8226. Here, we
observed a similar effect of co-culture with RPMI-8226, in
which there was a clear inhibition of Homeobox and osteogenic
gene expression coupled with hypermethylation of these loci
(Fig. 3G, H).
Altogether, these results support the notion that MM cells not
only are capable of inducing changes in the global methylome of
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Dual targeting of DNMTs and G9a restores Homeobox gene
expression in vitro and promotes osteogenic differentiation of
mesenchymal precursors. Gene expression analysis of DNMTs in
MSCs from HD and MM patients co-cultured with MM cells
obtained from a previous study41 showed an aberrant upregula-
tion of the DNA methyltransferase DNMT1 (Fig. 4A). DNMT1
interacts with the methyltransferase G9a to coordinate DNA and
H3K9 methylation during cell replication42 promoting tran-
scriptional silencing of target genes. Moreover, G9a can suppress
transcription by inducing DNA methylation in addition to its
activity as a chromatin remodeler43. In this regard, we hypothe-
sized that the dual inhibition of DNMT1 and G9a could reactivate
hypermethylated and silenced genes of MSCs from MM patients
preserving their osteogenic potential and therefore preventing
myeloma-associated bone loss. Thus, we utilized a dual inhibitor
of DNMTs and G9a, termed CM-272, which has been previously
described to have a potent therapeutic response, both in vitro and
in vivo, in other neoplasias44–47.
We first checked the effect of CM-272 on the cell viability of
mesenchymal progenitors and we selected a dose (50 nM) with no
significant toxicity in order to perform further experiments
(Fig. 4B). CM-272 treatment was able to restore the expression of
Homeobox genes (HOX-A6, -A9, -A10, -C9, PITX1, and RUNX2)
that were epigenetically repressed in MSCs from MM patients
(Fig. 4C). Mechanistically, we observed a loss of DNA methyla-
tion in the promoter region of the majority of the aforementioned
genes after CM-272 treatment in MM-MSCs (Fig. 4D). We then
checked the levels of the inactive chromatin mark H3K9me2, a
hallmark of methyltransferase G9a activity, at these gene
promoters upon CM-272 treatment. The chIP-qPCR analysis
showed a decrease in H3K9me2 levels at the promoter regions of
Homeobox genes after CM-272 treatment (Fig. 4E). Taken
together, our results suggest that CM-272 acts in vitro by
inhibition of both DNMT and G9a methyltransferase activity.
Next, we addressed whether targeting DNMT and G9a may
have a role in regulating osteogenic differentiation. For this
purpose, we cultured MSCs from myeloma patients in osteogenic
media to obtain differentiated OBs in the presence or absence of
CM-272. As observed in Fig. 4F, G, CM-272 was able to increase
ALP activity in early-stage OBs. Furthermore, CM-272 treatment
was able to upregulate the relative expression of several late bone
formation markers (namely, bone siaploprotein, osteopontin, and
osteocalcin) in MSCs from myeloma patients (Fig. 4H).
Previous research has described that MM cells exert their effect
on MSCs through both direct cell–cell contact and soluble factor
mechanisms11,48. Our main data show that direct myeloma-MSC
co-culture conditions are able to induce changes in the MSC
methylome; however, it would be of particular interest to
investigate whether MM cells may also mediate the same changes
only through soluble factor mechanisms. For this purpose,
utilizing a transwell system avoiding contact between both cell
types, we observed that soluble factor secreted by MM.1S and
RPMI-8226 cell lines were sufficient to change the expression of
several OB-relevant genes in healthy MSCs, including RUNX2,
SPP1, IBSP, and HOXB7 (Fig. 5A), concordantly to direct co-
culture. Furthermore, treatment with the dual inhibitor CM-272
was able to partially reverse those changes in gene expression
mediated by soluble factors secreted by MM cells (Fig. 5A).
Changes in gene expression were accompanied by inverse
changes in DNA methylation in some of the genes (IBSP,
HOXB7) (Fig. 5B), which were also observed to at least be
partially reversed by CM-272. However, for some other genes
such as RUNX2 and SPP1, transwell co-culture with MM cells
induced minimal effect on DNA methylation, suggesting that
direct cell–cell contact may be required. Moreover, CM-272 was
able to partially reverse the MM cell lines-mediated inhibitory
effect on OB mineralization (Fig. 5C). Altogether, these results
suggest that MM cells at least partially exert its effects on MSCs
through secretory mechanisms, and treatment with CM-272 was
able to reserve these effects through the inhibition of DNA
methylation.
CM-272 not only controls tumor burden but also prevents the
myeloma-associated bone loss. To test the effect of CM-272 in
the context of MBD, we used an established murine model of
bone marrow-disseminated myeloma. After equivalent engraft-
ment of myeloma cells (RPMI-8226-luc) was verified by biolu-
minescence measurement, mice were treated for 4 weeks with
CM-272 as described in Methods. Compared with the vehicle
control group, CM-272 controlled tumor progression as mea-
sured by bioluminescence (Fig. 6A) or by serum levels of hIgλ
secreted by RPMI-8226 cells (Fig. 6B). Representative microCT
images at the metaphyses of distal femurs showed a tumor-
associated bone loss in vehicle-treated mice, in contrast with
trabecular structures observed in CM-272-treated animals
(Fig. 6C). In the vehicle control group, 3D reconstruction images
of distal femurs revealed a marked bone loss evidenced by a thin
trabecular network (in red) but also by loss of cortical bone (in
gray) in vehicle-treated mice (Fig. 6D). By contrast, CM-272-
treated mice presented a gain in both trabecular and cortical bone
(Fig. 6D). This was also reflected by bone morphometric para-
meters that resulted in increased trabecular bone volume, occu-
pancy, and connectivity and reduced trabecular separation in
CM-272-treated animals, as compared with vehicle control
(Fig. 6E). Finally, these findings correlated with a significant
increase in serum levels of the bone formation marker P1NP
analyzed after CM-272 treatment compared to untreated control
(Fig. 6F). In summary, these data demonstrate that CM-272
exerts in vivo anti-myeloma activity along with bone-anabolic
effects in human MM-bearing mice.
Fig. 2 DNA methylation changes are associated with differential gene expression of Homeobox genes in MSCs from MGUS, SMM and MM patients. A
Venn diagrams showing differentially methylated or downregulated (upper) and upregulated (lower panel) genes when comparing MGUS (blue), SMM
(orange), and MM (red) samples with healthy individuals. B Gene ontology (GO) enrichment analysis of CpG sites undergoing DNA methylation and gene
expression changes in MSCs of patients compared to controls using the GREAT online tool. A binomial test was performed to calculate statistical
significance. C Heatmaps showing gene expression of Homeobox and other OB-related genes associated with differentially hyper- (left) or hypomethylated
(right) CpG sites. Heatmaps are grouped according to the genomic location (promoter, TSS, 5′, exon, intron, intergenic, 3′ or non-coding region) of
analyzed CpG sites. Color scale ranging from light yellow to dark blue represents low to high expression levels. D Scheme depicting differentially
methylated and variable CpG sites located in the Homeobox genes (HOX-A, -B, and -C clusters) and PITX1. Dark blue lines indicate hypomethylated DMPs,
light blue lines indicate hypomethylated DVPs, dark red lines indicate hypermethylated DMPs and light red lines indicate hypermethylated DVPs associated
with MGUS, SMM, and MM condition. E DNA methylation analysis by pyrosequencing of selected CpGs located at the promoter regions and F gene
expression of HOXA6, -A9, -A10, -B7, -C9, PITX1, and RUNX2 in MSCs from healthy controls (dark blue; n= 17), MGUS (light blue; n= 8), SMM (orange; n
= 8), and MM (n= 16) patients. Gene expression was normalized against RPL38. Box plots represent median ± IQR and whiskers represent maximum and
minimum. Statistical significance was calculated using unpaired two-tailed Student t-tests (*p-value < 0.05, **p-value < 0.01, and ***p-value < 0.005).
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To further examine the in vivo effect of CM-272 on DNA
methylation of myeloma-associated MSCs, we performed reduced
representation bisulfite sequencing (RRBS) analysis of MSCs
isolated from vehicle- and CM-272-treated myeloma-bearing
mice using healthy mice as controls. First, we observed significant
alterations in the DNA methylome of MSCs from myeloma-
bearing mice compared to healthy mice (Supplementary Data 8).
Myeloma-bearing mice that were treated with CM-272 displayed
a partial reversion of aberrant hypermethylation of MSCs caused
by the presence of myeloma cells (Fig. 6G). These DNA
methylation changes occurred at genomic loci enriched for genes
involved in cell commitment and differentiation, such as
Homeobox genes (Fig. 6H). Specifically, we were able to identify
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treated MSCs compared to healthy controls at the same genomic
loci previously identified in human MM-MSCs, including
HOXA7, -B4, -B7, -B9, and -D10 (Fig. 6I and Supplementary
Data 9). Importantly, CM-272 treatment was able to restore the
DNA methylation levels at these loci to resemble that of healthy
mice, which was concomitant with the reduced tumor burden as
well as bone loss recovery observed in these mice (Fig. 6I).
Discussion
The pathogenic transition from premalignant stages to active
MM is complex and not well understood. One example of this
complexity is that although all MM cases emerge from the pre-
existing asymptomatic MGUS/SMM stage, not all MGUS
progress into MM and may exist as a stable and independent
disease. Nevertheless, despite being an asymptomatic stage,
transformed plasma cells in MGUS present cytogenetic
alterations similar to that of myeloma plasma cells, as well as
significant abnormalities in bone remodeling49,50. This indi-
cates that both genetic and microenvironmental alterations
exist from the early stages of the disease. In our study, we
show that epigenetic alterations in MSCs already occur in the
early asymptomatic stages of both MGUS and SMM, and
although many alterations are shared between all stages, the
majority of DNA methylation changes are specific to each
stage. These results are in accordance with previous studies
that indicate the existence of stage-specific epigenetic altera-
tions during MM progression in malignant plasma cells51,52.
This phenomenon could be explained by the expansion of sub-
populations of MSCs during MM disease progression, which
may favor tumor development and drug resistance, similar to
what was observed to occur in MM cells53,54.
Deregulation of methylome in MM-MSCs mediates tran-
scriptional and phenotypical alterations. Interestingly, many
genes of the Homeobox family displayed both epigenetic and
transcriptional dysregulation in patient MSCs, and these
changes were observed in earlier stages of the disease. In this
regard, members of the HOX family have been recently
described to be key drivers of OB differentiation, in which
their expression is fine-tuned by demethylation of their pro-
moters during the osteogenic process55. Furthermore, we
observed that healthy MSCs exposed to MM cells, similarly to
that observed in patient MSCs, not only displayed an altered
methylome but also showed impaired MSC-to-OB differ-
entiation, as previously described20. We also observed that
some of these methylome changes in MSCs occur in the
absence of direct cell–cell contact with MM cells, suggesting
the contribution of secretory mechanisms. Hence, our results
suggest that the impairment of osteogenesis in all stages of
MM arises from early transcriptional deregulation of
Homeobox genes, and altered DNA methylation may be the
primary mediator in this process. Nevertheless, we cannot
overlook the limitations of our in vitro studies, as other cell
types of the BM microenvironment may also play important
roles in perpetuating the methylome alterations observed
in MSCs.
Although the biology of MBD is relatively well described, there
is still a lack of pharmacological treatments to improve bone loss.
Clinically approved bone-modifying agents for the treatment of
MBD include bisphosphonates56, which inhibit bone resorption
by suppressing OC activity, and denosumab57, a monoclonal
antibody against the osteoclastogenic cytokine RANKL. However,
these drugs only target the OC compartment, and bone disease
persists due to the absence of bone formation. Thus, therapeutic
agents targeting OBs are needed. In this study, we demonstrated a
strategy for treating MBD by targeting aberrant DNA methyla-
tion in MSCs. Firstly, we showed that co-culture of healthy MSCs
with MM cell lines yielded epigenetic and transcriptional changes
similar to that observed for MSCs from myeloma patients, and
treatment with CM-272 was able to at least partially reverse these
changes. Additionally, this agent promoted the ability of MSCs to
differentiate into OBs. These in vitro effects on bone were mir-
rored in a mouse model of disseminated MM. Of note, CM-272
treatment not only prevented bone loss by bone-anabolic effects
but also showed anti-myeloma activity. This is in line with pre-
vious reports showing that DNMTs are targets for the treatment
of MM58–60 and also for improving the osteogenic differentiation
ability of MSCs61. Additionally, we cannot discard the possibility
that the observed effects on tumor growth inhibition may be a
consequence of the impairment of the cross-talk between MSCs
and MM cells. Moreover, the dual targeting effects of CM-272
also inhibit the dimethylation of H3K9, which has been described
to be crucial in the establishment of DNA methylation42,43. It is
therefore rational to envision that the bone-anabolic effects
mediated by CM-272, both in vitro and in vivo, involves the
reversion of aberrant hypermethylation at Homeobox loci and
other OB-related genes in the MSC population. Nevertheless, it is
possible that reduced tumor burden could be partially responsible
for restoring the bone-forming capacities of MM-MSCs.
In summary, our findings highlight the existence of aberrant
DNA methylation patterns in the BM-derived MSC population
which may impact myeloma progression and the development of
MBD. Moreover, our preclinical results support the idea that
therapeutic targeting of aberrant DNA methylation would result
in an anti-myeloma effect and preservation of the appropriate
osteogenic differentiation of MSCs to combat myeloma bone
disease.
Fig. 3 MSCs from healthy donors recapitulate DNA methylation changes observed in MSCs from MM patients upon interacting with MM plasma cells.
A Scheme depicting workflow (left panel) and sorting strategy (right panel) for selecting CD13+MSCs after 14 days of co-culture with the MM.1S cell line.
B Gene expression analysis of IL1B, IL6, and HGF, normalized against RPL38, of the hMSC-TERT cell line (HD-MSC) co-cultured with the MM.1S cell line for
14 days. Expression levels were normalized against MSCs in monoculture. Data are represented as the mean ± SEM from three independent experiments.
C ALP activity and matrix mineralization were assessed in differentiated osteoblasts from HD-MSCs in the presence (HD-OB+ CM-MM) or absence (HD-
OB) of conditioned media from the MM.1S cell line (CM-MM). Representative images of each experimental condition are shown. Barplot represents the
mean ± SEM from six independent experiments, and a paired two-tailed t-test was performed to evaluate statistical significance (***p < 0.005). D Heatmap
showing differentially methylated CpG sites (eBayes-moderated paired t-test *p < 0.05) in sorted HD-MSCs (three independent donors) in monoculture
(HD1-3) or co-cultured with the MM.1S cell line (HD1-3MM) for 14 days that overlaps with previously identified DMPs. The color scale from blue to red
represents low to high methylation levels. E GO enrichment analysis of DMPs in HD-MSCs co-cultured with the MM.1S cell line overlapping with myeloma-
associated DMPs analyzed using the GREAT online tool. p-values were calculated using a binomial test. F Bar plots showing β-values obtained from the
DNA methylation array presented in D, representing mean and ±SEM of three independent experiments. G DNA methylation and H gene expression levels
of DMPs validated in HD-MSCs monoculture (blue) or co-cultured with MM.1S (orange) or RPMI-8226 (red) cell lines as indicated. Gene expression data
were normalized against RPL38 and all data were normalized against HD-MSC monoculture. Statistical significance was calculated using paired one-tailed
Student t-tests and bar plots represent mean ± SEM of 3–5 independent experiments (*p-value < 0.05, **p-value < 0.01, and ***p-value < 0.005).
ARTICLE NATURE COMMUNICATIONS | https://doi.org/10.1038/s41467-020-20715-x
8 NATURE COMMUNICATIONS |          (2021) 12:421 | https://doi.org/10.1038/s41467-020-20715-x | www.nature.com/naturecommunications
Methods
Participants. BM samples were obtained from the iliac crest of patients with newly
diagnosed MGUS (n= 10), SMM (n= 8), and MM (n= 9), according to the
International Myeloma Working Group criteria. BM samples from healthy controls
(n= 8) were obtained from participants undergoing orthopedic surgery not related
to oncology disease. Each sample was obtained after receiving the informed written
consent of all participating subjects and following approval from the committees
listed below for obtaining them and for the study protocol using them. The study
was approved by the Cancer Research Center–IBMCC Review Board (CICIC 2015/
02156), the Clinical Ethics Committee for drug research in the Salamanca Health
Area (CEIC 73/07/2015), the Clinical Research Committee of the Bellvitge Uni-
versity Hospital (ref. PR076/15) and the Research Ethics Committee of the Uni-
versity of Navarra (ref. 2017.218). Clinical characteristics of MGUS, SMM, and
MM patients are listed in Supplementary Table 2.
Inhibitor. CM-272 (dual DNMTs and G9a inhibitor) was synthesized at the Center
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Cell lines. The human multiple myeloma cell line MM.1S was provided by Dr.
Steven Rosen (Northwestern University, Chicago, IL), whereas RPMI-8226 cells
were purchased from the American Type Culture Collection. The human
mesenchymal stem cell (MSC) line immortalized by expression of the telomerase
reverse transcriptase gene (hMSC-TERT) was a generous gift from Dr. D Campana
(Department of Pediatrics, Yong Loo Lin School of Medicine, National University
of Singapore, Singapore). Both cell lines were cultured in RPMI 1640 medium
supplemented with 10% heat-inactivated fetal bovine serum (FBS), 100 U/ml
penicillin and 100 mg/ml streptomycin, and 1% L-glutamine. All the cell culture
media and reagents were purchased from Invitrogen (Paisley, UK). All cell types
were cultured at 37 °C in a humidified atmosphere in the presence of 5%
CO2–95% air.
Bone marrow-derived MSC isolation and culture. MSCs were isolated and
characterized as described by Garayoa et al.17. Briefly, bone marrow aspirates were
obtained from the iliac crest and subjected to centrifugation on Ficoll-Paque (GE
Healthcare, Uppsala, Sweden) to obtain mononuclear cells (BMMCs). BMMCs
were plated and plastic-adherent cells were expanded until passage 3 (P3) in low-
glucose DMEM supplemented with 10% heat-inactivated fetal bovine serum, 100
U/ml penicillin, 100 mg/ml streptomycin, and 1% L-glutamine. Selected MSCs from
both MM patients (n= 4) and healthy donors (n= 4) at P3 were tested to meet
minimal criteria as defined by the International Society for Cellular Therapy for
multipotent mesenchymal stromal cells63. Specifically, MSCs were evaluated by
FACS for positive expression of CD73, CD90, CD105, CD44, and CD166 and
negative staining for HLA-DR and hematopoietic markers (CD19, CD34, and
CD45) (Supplementary Fig. 3A). In addition, the capability to differentiate into
osteoblast, adipocyte, and chondrocyte was assessed (Supplementary Fig. 3B–D).
Analyses and experiments were performed with MSCs at P3, with a maximum of
3 weeks at each passage.
DNA and RNA isolation and quantification. Genomic DNA was isolated by the
proteinase K method or using the Maxwell® RSC Cell DNA Purification Kit
(Promega) for samples containing low cell number. RNA was isolated using
Maxwell® RSC simplyRNA Cells Kit (Promega) according to the manufacturer’s
instructions. DNA and RNA were quantified using Qubit® DNA Assay Kit
(Invitrogen) or NanoDrop ND-1000, respectively.
DNA methylation and gene expression profiling using arrays. DNA samples
were bisulfite-converted using an EZ DNA methylation kit (Zymo Research,
Orange, CA) and hybridized onto an Infinium® MethylationEPIC BeadChip array
(Illumina, Inc.). The array platform allows the assessment of DNA methylation
status at >850,000 CpG sites at single-nucleotide resolution and covers 99% of
RefSeq genes and 95% of CpG islands with an average number of six probes per
island.
RNA samples were obtained from healthy donors (n= 8), MGUS (n= 10),
SMM (n= 10), and MM patients (n= 24) at diagnosis and 100 ng of excellent
quality RNA (RIN > 9) was hybridized onto a GeneChip Human Gene 1.0 ST
(Affymetrix).
Quality control, data normalization, and detection of differentially methylated
and variable CpGs. Methylation array data were processed in the statistical lan-
guage R v4.0 in RStudio 1.3 (https://rstudio.com) using methods from the Bio-
conductor libraries minfi (v1.36.0), lumi (v2.42.0), and limma (v3.46.0)64–66.
Probes were annotated using IlluminaHumanMethylationEPICmanifest v0.3.067.
Data quality was assessed using the standard pipeline from the minfi package. The
data were quantile-normalized and chromosomes X and Y were removed to avoid
technical and biological bias. Furthermore, we discarded the DNA methylation
changes associated with the long-term culture of BM-MSCs based on the previous
studies68. M values (log2-transformed β-values) were utilized to obtain a p-value
between sample groups by an eBayes-moderated paired t-test using the limma
package, in which age and sex were added in the interaction matrix. For the
analysis of MSCs isolated from MM patients and healthy controls, we considered a
probe to be differentially methylated when the difference between the mean of β at
disease versus control was over 10% (Δβ ≥ 0.1) and the statistical test was sig-
nificant (**p < 0.01). In addition, we used the iEVORA algorithm69, provided by
matrixTests v0.1.9 (https://CRAN.R-project.org/package=matrixTests), to desig-
nate a probe as differentially variable. This algorithm detects the homogeneity of
variances using the Bartlett’s test (FDR < 0.05) and then selects those probes whose
t-test is significant (*p < 0.05) in order to regularize the variability test which is
overly sensitive to single outliers.
To evaluate the contribution of various covariates, including age and sex, we
performed either a Pearson correlation or Wilcoxon signed-rank test depending on
whether the covariate of interest was continuous or categorical. This is represented
in Supplementary Fig. 4, in which a covariate with a p-value < 0.05 was considered
to significantly contribute to DNA methylation.
For the direct co-culture of healthy MSCs with MM cell line, samples were
normalized utilizing Noob and Quantile normalizations provided by minfi. The
paired analysis was performed and a probe was considered differentially
methylated if Δβ was more than 10% and p-value was <0.01.
Gene ontology, motif, and chromatin state analysis. Functional annotation
enrichment analysis was performed using GREAT tool v4.0.4 (http://great.stanford.
edu/public/html)70 by mapping differentially methylated CpG site to the single
nearest gene. CpGs annotated in the EPIC 850K array were used as background.
GO categories with p-value of <0.01 were considered significantly enriched.
For TF binding motif analysis, HOMER motif discovery software v4.5 was
used27, where a 500 bp-window upstream and downstream of the differentially
methylated CpG sites was applied. CpGs annotated in the EPIC array were used as
background.
To analyze chromatin states associated with DMPs, ChromHMM26 data sets
from healthy donor MSCs were downloaded from the UCSC Genome Browser
(https://genome.ucsc.edu/). Overlap was performed in R using the GenomicRanges
package v1.42.071, where CpGs annotated in the EPIC array were used as
background.
Gene expression array normalization and analysis. Data processing and nor-
malization were carried out using the R statistical language. Background correction
was performed using Robust Microarray Analysis (RMA) normalization provided
by oligo package v1.54.172 and probes were annotated utilizing the hugene10st-
transcriptcluster.db R package v8.7.073. Average expression was calculated for
probes mapping to the same gene. For comparisons between groups, eBayes-
moderated t-test provided by the limma R package65 was applied, where a p-value
< 0.05 was considered statistically significant. DMPs were mapped to the nearest
gene utilizing the GREAT online tool, and overlap with differentially expressed
genes were performed by overlapping gene names.
Fig. 4 CM-272 treatment reactivates Homeobox gene expression and promotes the osteogenic differentiation of MSCs from MM patients. A
Expression of DNA methyltransferases 1, 3A, and B (DNMT1, -3A, and -3B) in HD and MM-MSCs co-cultured for 24 h with the MM.1S cell line comparing
with monoculture as assessed by the GeneChip Human Gene 1.0 ST Array. Box plots present mean ± SEM for 8 healthy donors and 9 MM patients.
p-values were calculated by paired two-tailed Student t-test (*p < 0.05, **p < 0.01). B MSCs from MM patients were treated with the indicated doses of
CM-272 for 72 h and subjected to MTT assay for viability. Mean and SEM are indicated on the line chart from 3 independent experiments. C Real-time RT-
PCR was performed to determine the expression of hypermethylated Homeobox genes (HOX-A6, -A9, -A10, -C9, PITX1, RUNX2) in MM-MSCs treated with
vehicle or 50 nM of CM-272 for 7 days. Box plots represent median ±IQR, with whiskers representing minimum and maximum, of 9 independent
experiments. A paired two-tailed Student’s t-test was performed to calculate statistical significance (*p < 0.05, **p < 0.01). D DNA methylation analysis by
pyrosequencing of selected CpGs located at the promoter regions of Homeobox genes in MM-MSCs treated with vehicle (gray) or CM-272 (blue) for
7 days. Bar plots present mean ± SEM for 3 independent experiments and paired two-tailed Student’s t-tests were performed (*p < 0.05). E ChIP assays
showing the H3K9me2 (blue) enrichment at the promoter regions of Homeobox genes in MM-MSCs treated with vehicle or CM-272 for 7 days. IgG (gray)
was used as a negative control. Data are shown as a relative enrichment of the bound fraction with respect to the input DNA. Bar plots present mean ±
SEM for 3 independent experiments and paired two-tailed Student’s t-tests were performed (*p < 0.05, **p < 0.01, and ***p < 0.005). ALP activity was
assessed in MM-MSCs (n= 3) cultured in osteogenic media in the presence of 25 nM (light blue) and 50 nM (dark blue) of CM-272, compared to vehicle
(gray), by F p-NPP hydrolysis and G NBT-BCIP. H Expression of osteoblastogenesis markers IBSP (bone sialoprotein), BGLAP (osteocalcin) and SPP1
(osteopontin) was checked by qRT-PCR in MM-MSCs cultured in osteogenic media in the absence (vehicle) or presence of CM-272. For F and H data are
shown as mean values ± SEM from three different experiments. Statistically significant tests (paired two-tailed Student’s t-tests) are represented as
*p < 0.05, **p < 0.01, and ***p < 0.005 between vehicle and CM-272 condition.
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Bisulfite pyrosequencing. For total DNA extraction, cells were lysed using lysis
buffer (50 mM Tris pH 8.8, 10 mM EDTA pH 8.3, 100 mM NaCl, 1% SDS) in the
presence of Proteinase K (Roche). Repeated centrifugation was performed to
separate nucleic acids from lipids, in which DNA was subsequently precipitated
using isopropanol and washed with 75 % ethanol. 100-300 ng of isolated DNA were
bisulfite (BS)-converted using EZ DNA Methylation-Gold™ Kit (Zymo Research,
CA, USA) according to manufacturers’ instructions. BS-converted DNA (~10 ng)
was used as a template for amplification by conventional PCR using IMMOLA-
SETM DNA Polymerase kit (Bioline, London, UK). PCR primers were designed
with the PyroMark Assay Design v2.0.2 software (Qiagen). PCR products were
pyrosequenced with the PyromarkTM Q24 system (Qiagen), according to the
manufacturer’s protocol.
Quantitative real-time PCR (qRT-PCR). Reverse transcription was performed
using the Transcriptor First Strand cDNA Synthesis Kit (Roche) according to the
manufacturer’s instructions. qRT-PCR was performed using LightCycler® 480 II
System with LightCycler® 480 SYBR Green Mix and data were analyzed with
LightCycler® 480 II Software, version 1.5, all provided by Roche. Reactions were
performed in triplicate for both the target and the housekeeping gene ribosomal
protein L38 (RPL38) used for normalization. Relative quantification of the target
gene expression was calculated by the comparative threshold cycle (Ct) method.
Co-culture system and MSC sorting. MSCs from healthy donors at passage 3 (8 ×
103 cells/cm2) or the hMSC-TERT cell line (10 × 103 cells/cm2) were first cultured
in 100 mm culture dishes until they reached ~85% confluency, and then MM.1S
cells (1:3 MSC:MM.1S ratio) were added in RPMI 1640 medium supplemented
with 10% FBS and antibiotics. MM cells were changed twice a week until day 14
when MSCs were recovered by trypsinization and flow cytometry-based sorting of
CD13+ cells (BD Biosciences). For transwell experiments, MSCs from healthy
donors were seeded on bottom chambers and MM.1S and RPMI-8226 cells were
seeded on PET membrane inserts containing 1 μm size pores to allow an exchange
of soluble molecules. Transwell experiments were performed as in direct co-
cultures. For OB differentiation studies, MSCs from healthy donors were cultured
in an osteogenic medium supplemented with 20% of conditioned media from the
MM.1S cell line. This medium was changed twice a week until day 10 (ALP
activity) or day 20 (OB mineralization). For the isolation of mouse MSCs, cells were
stained with a combination of CD45-PE, Ter-119-PE, Sca-1-FITC, and PDFGRα-
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Fig. 5 CM-272 restores the gene expression levels and suppression of mineralization in MSCs from healthy donors exposed to MM cells. HD-MSCs
(MSC; blue) were co-cultured with MM.1S (orange) or RPMI-8226 (red) cell lines separated by a transwell system in the presence (darker shade) or
absence (lighter shade) of CM-272. A Relative expression and B DNA methylation of genes RUNX2, SPP1, IBSP, and HOXB7 was assessed. Gene expression
was by normalization against RPL38. Bar plots represent mean ± SEM of 3–5 independent experiments and statistical significance was calculated by paired
one-tailed Student’s t-test (*p < 0.05, **p < 0.01). C Mineralization was assessed by alizarin red staining in differentiated OBs from HD-MSCs co-cultured
with MM.1S or RPMI-8226 cell lines in the presence or absence of CM-272. Representative micrographs show matrix mineralization by alizarin red staining
of corresponding differentiated OBs. Data are represented as the mean ± SEM from three independent experiments and paired two-tailed Student’s t-tests
were performed (*p < 0.05, **p < 0.01).
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experiments were performed by the Flow Cytometry Core Facility at Germans
Trias i Pujol Research Institute utilizing FACSAria II cell sorter and analyzed using
BD FACSDiva version 6.1.1 (BD Biosciences, San Jose CA).
OB differentiation assays. OBs were generated from mesenchymal precursors by
culture in osteogenic medium (containing 5 mM β-glycerophosphate and 50 mg/ml
ascorbic acid) and assayed as in Garcia-Gomez et al.75. Briefly, primary MSCs
(P2–3) were cultured in osteogenic medium for the analysis of alkaline phosphatase
(ALP) activity, expression of osteogenic markers (day 10), and formation of
mineralized-nodules formation (day 20). ALP activity was determined by hydro-
lysis of p-nitrophenylphosphate (Sigma-Aldrich) into p-nitrophenol and NBT/
BCIP substrates (Roche), whereas mineralization was assessed by quantitative
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measured by Multiskan Sky Microplate Spectrophotometer via SkanIt PC software
(ThermoFisher).
MTT assay. MSCs were seeded in 96 well plates and treated with increasing
concentrations of CM-272. MTT was added at a final concentration of 0.5 mg/ml
and incubated at 37 °C for 1 h. Cells were then washed with PBS and incubated in
the dark for 10 min in the presence of dimethyl sulphoxide. Absorbance at 570 nm
was measured utilizing the Multiskan Sky Microplate Spectrophotometer.
Flow cytometry antibodies. Prior to analysis and sorting by flow cytometry,
distinct amounts of MSCs were stained with fluorochrome-conjugated antibodies.
Antibody specifications and concentrations used were the following: CD13-PE (BD
Biosciences, 347406), CD45-PE (eBioscience, 12-0451-81), Ter-119-PE
(eBioscience, 12-5921-81), Sca-1-FITC (eBioscience 11-5981-81), PDFGRα-APC
(BD Biosciences, 562777), CD44-FITC (BD Biosciences, 347943), CD19-PerCP
(BD Biosciences, 332780), CD90-FITC (BD Biosciences, 555595), HLA-DR-PerCP
(BD Biosciences, 347402), CD14-FITC (BD Biosciences, 345784), CD166-PE (BD
Biosciences, 559263), Cd45-PercCPcy5.5 (BD Biosciences, 332784), CD34-FITC
(Invitrogen, 11-0349-42), CD73-PE (BD Biosciences, 550257), CD105-APC (R&D
System, FAB10971A).
Chromatin immunoprecipitation (ChIP)-quantitative PCR. MSCs (15 × 103 cells
per IP) were cross-linked with 1% formaldehyde for 15 min and subjected to
chromatin immunoprecipitation after sonication. ChIP-qPCR assays were per-
formed using LowCell ChIP kit™ protein A (Diagenode) and the antibody (5 μg)
against H3K9me2 (H3K9me2 Abcam ChIP-grade, clone:mAbcam 1220, Ref:
ab1220, Lot:GR45436-1). Data are represented as the ratio of the bound fraction
over the input for each histone modification or factor. IgG was used as a negative
control. Primer sequences were designed as close as possible from the CpG
undergoing methylation changes. Primer sequences are shown in Supplementary
Table 3. These experiments were performed with three biological replicates of each
origin.
In vivo model. Animal experiments were conducted according to relevant ethical
regulations for the use of laboratory animals and after acquired permission from
the University of Salamanca Committee for animal experimentation (ref #
0000061). BALB/c-Rag2null IL2rγnull (BRG) mice // or NOD-scid IL2rγnull (NSG)
mice were bred and maintained in the SPF area of the University of Salamanca
Animal Facility with controlled environment conditions (20–23 °C, 12:12 light/
dark cycles, 30–70% relative humidity) and fed ad libitum. CM-272 was solubilized
in 0.9% saline solution. RPMI-8226-luc cells (8 ×106) were injected intravenously
into 8-week-old NOD-SCID-IL-2Rγ−/− (NSG) mice (Charles River Laboratories)
and tumor development was monitored by noninvasive bioluminescence imaging
(BLI) with a Xenogen IVIS 50 system (Caliper Life Sciences). After 4 weeks, ani-
mals were randomized into two groups (n= 6/group) receiving vehicle (0.9% saline
solution) or CM-272 (5 mg/kg, 5 times/week by intraperitoneal injection).
Microcomputed tomography analysis. One femur of each animal was fixed in
10% formalin in order to preserve bone microarchitecture. 3D X-ray tomographic
images were acquired using a Quantum-GX microCT (Perkin Elmer) with the
following parameters: 80 kVp X-ray source voltage, 120 μA current, and the high-
resolution scan protocol for a total acquisition time of 14 min and a gantry rotation
of 360 degrees. The tomographic three-dimensional images containing the entire
bone yielded a total of 512 slices, with isotropic 50 microns voxel size and a
resolution of 512 × 512 pixels per slice. To perform the bone histomorphometry
analysis a (10 × 10 × 10 mm) ROI containing the bone metaphysis was defined and
subsequently reconstructed from the original scan at a resolution of 20 microns per
voxel using the Quantum 3.0 software.
Analysis of trabecular microarchitecture in the distal femur was carried out
using ImageJ v1.8.076. First of all, cortical and trabecular bones were segmented
from the CT volume. To this end, the following steps were followed: (i)
segmentation of the entire bone volume by thresholding the original volume to
obtain a 3D binary mask; (ii) segmentation of empty volumes inside the cortical
volume (trabecular-free zones) using logical operators over filled vs. unfilled
versions of the result of step i; (iii) segmentation of the interior volume of the
cortical bone by applying 10 morphological dilations followed by 10 morphological
erosions to the 3D mask obtained in step ii; (iv) segmentation of the cortical bone
by performing an XOR logical operation between the masks obtained in steps i and
iii; and finally, (v) segmentation of the trabecular bone by performing an AND
logical operation between the masks obtained in steps i and iii. The final cortical
and trabecular bone segmentations were further refined by applying a median filter
to remove noise in the respective 3D masks. Cortical and trabecular bone volumes
were then calculated by applying the segmentation masks on the original volume.
From the obtained trabecular masks, histomorphometry parameters were
calculated using the BoneJ plugin (version 1.4.2)77. Finally, bone 3D reconstruction
and visualization were performed using Amira 5.2 software (ThermoFisher
Scientific).
ELISA. Serum levels of human Igλ (indicating tumor burden) and N-terminal
propeptide of type I procollagen (P1NP) (indicating bone formation) were mea-
sured in mice sera using the Human Lambda ELISA kit (Bethyl Laboratories,
Texas, USA) and Rat/Mouse PINP EIA kit (Immunodiagnostic Systems, East
Boldon, UK), respectively, following manufacturers’ instructions. Absorbance was
measured using the Multiskan Sky Microplate Spectrophotometer.
Reduced representation bisulfite sequencing (RRBS). Sorted MSCs from three
groups (healthy, vehicle-treated, and CM-272-treated mice) were pooled in order
to obtain a significant number of cells for performing the RRBS-seq. Isolated DNA
from each pool was subjected to the RRBS pipeline as previously described78. In
brief, purified DNA was digested with MspI and subjected to bisulfite conversion.
Following PCR amplification, RRBS libraries were generated from sequenced DNA
following previously published procedures (http://code.google.com/p/bsmap/
downloads/). Downstream normalization and analyses were performed following a
previously published pipeline (http://rrbs-techdev.computational-epigenetics.org/).
CpG annotation and GO enrichment analysis was performed utilizing the GREAT
online tool.
Primers. All primers used are listed in Supplementary Table 3.
Fig. 6 CM-272 prevents tumor-associated bone loss besides reducing multiple myeloma tumor burden. RPMI-8226-luc cells (8 × 106) were
intravenously injected into NSG mice. After 4 weeks, mice were randomized into 2 groups [receiving vehicle (gray) and CM-272 (red); n= 6/group] and
treated for additional 4 weeks with dosing and regimen schedules as specified in Supplementary Methods. Tumor dissemination was checked by
A bioluminescence measurement and B serum levels of human Igλ secreted by RPMI-8226-luc cells at specified time points. Line plots represent mean and
SEM. Box plots represent median ±IQR, with whiskers representing the minimum and maximum. Statistical significance was determined utilizing paired
two-tailed Student’s t-test (*p < 0.05, **p < 0.01). C Representative microCT cross-sections at the metaphyses of distal femurs in a vehicle and CM-272-
treated mice in transversal (upper) and sagittal (down) planes. D Transversal (left) and sagittal (right) planes of corresponding 3D renderings from
microCT images at distal femurs (trabecular bone in red, cortical bone in gray). E Trabecular bone morphometric parameters from microCT images were
quantitated for trabecular bone volume, occupancy, connectivity, and separation. F Serum levels of the bone formation marker P1NP were quantified by
ELISA. Graphs represent mean values ± SEM with whiskers representing minimum and maximum values. CM-272-treated (red) mice were compared to
the vehicle group (gray), where *p < 0.05; **p < 0.01 versus the vehicle control group. G Box plots showing DNA methylation levels of pooled MSCs
obtained from healthy, vehicle- and CM-272-treated animals corresponding to hypermethylated CpGs between healthy and tumor-bearing animals. H GO
enrichment analysis of CpG sites undergoing DNA hypermethylation changes in vehicle-treated MSCs versus MSCs from healthy mice. I Heatmap showing
normalized DNA methylation levels of individual CpGs at selected Homeobox loci among animal groups. Data pooled from mice (n= 6) for each group
with sufficient RRBS coverage (≥5 valid sequencing reads per CpG). <0.01 by paired two-tailed Student’s t-test. G Box plots showing mean ± SEM, with
whiskers representing minimum and maximum values, of DNA methylation levels of pooled MSCs obtained from healthy (blue), vehicle- (gray), and CM-
272-treated (red) animals corresponding to hypermethylated CpGs between healthy and tumor-bearing animals. A paired two-tailed Student’s t-test was
performed to calculate statistical significance (****p < 0.001). H GO enrichment analysis of CpG sites undergoing DNA hypermethylation changes in
vehicle-treated MSCs versus MSCs from healthy mice. p-values were calculated utilizing a binomial test. I Heatmap showing normalized DNA methylation
levels of individual CpGs at selected Homeobox loci among animal groups. The color scale ranges from white to red, representing low to high levels of DNA
methylation. Data pooled from mice (n= 6) for each group with sufficient RRBS coverage (≥5 valid sequencing reads per CpG).
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Statistical analysis. Data are expressed as mean ± SEM and the n value for each
in vitro assay is specified in the corresponding figure legend. Statistical analyses
were carried out with Prism version 6.0 (GraphPad) and were performed using a
two-tailed Mann–Whitney U test or Student’s t-test.
Reporting summary. Further information on research design is available in the Nature
Research Reporting Summary linked to this article.
Data availability
The DNA methylation and expression data supporting the findings of this study have
been deposited in the NCBI’s Gene Expression Omnibus database under the accession
code GSE137419. This SuperSeries (GSE137419) is composed of the following SubSeries:
GSE137360 (methylation), GSE137369 (expression), and GSE137416 (methylation II).
All the other data supporting the findings of this study are available within the article and
its supplementary information files and from the corresponding author upon reasonable
request. Source data are provided with this paper.
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